In April, after reviewing a business model that incorporated RNAi-based drug development, Cenix Biosciences made the decision to refocus strictly on offering RNAi reagent design, target discovery, and target validation services.
In April, after reviewing a business model that incorporated RNAi-based drug development, Cenix Biosciences made the decision to refocus strictly on offering RNAi reagent design, target discovery, and target validation services.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.